Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer

Curr Opin Oncol. 1999 May;11(3):187-90. doi: 10.1097/00001622-199905000-00009.


The overall survival of patients with squamous cell cancer of the head and neck has not significantly improved over the past 2 decades. Preclinical studies suggest that combining a monoclonal antibody to the epidermal growth factor receptor with irradiation or chemotherapy agents active in squamous cell cancer of the head and neck could increase treatment efficacy. Completed phase I studies have shown these combinations to be both feasible and tolerable. Phase III studies are now beginning to establish firmly the efficacy of this innovative new approach.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / radiotherapy
  • Carcinoma, Squamous Cell / therapy*
  • Cisplatin / therapeutic use
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • ErbB Receptors / immunology*
  • Head and Neck Neoplasms / drug therapy
  • Head and Neck Neoplasms / radiotherapy
  • Head and Neck Neoplasms / therapy*
  • Humans


  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • ErbB Receptors
  • Cisplatin